5 Best Penny Stocks to Buy Now
Asthika Goonewardene at Truist gave Compugen Ltd. (NASDAQ:CGEN) stock a target price of $4 and maintained a Buy rating on the stock in a research note issued on August 23.
Posts Tagged ‘NASDAQ:CLVS’
15 Best Penny Stocks To Invest In
The US equity market has been volatile since the start of 2022. The Dow 30 Index extended an eight-week consecutive losing streak.
These 5 Stocks Are Skyrocketing Today
In this article, we take a look at five stocks that are skyrocketing today.
Is CLVS A Good Stock To Buy Now?
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (Recession is Imminent: We...
Hedge Funds Are Dipping Their Toes Back Into Clovis Oncology Inc (CLVS)
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data.
Hedge Funds Never Been Less Bullish On Clovis Oncology Inc (CLVS)
How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies.
Did Hedge Funds Drop The Ball On Clovis Oncology Inc (CLVS) ?
Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great...
Were Hedge Funds Right About Dumping Clovis Oncology Inc (CLVS)?
With the first-quarter round of 13F filings behind us it is time to take a look at the stocks in which some of the best money managers in the world preferred to invest or sell...
Hedge Fund and Insider Trading News: Ray Dalio, Tom Steyer, Bodenholm Capital, Balyasny Asset Management, AQR Capital, Magellan Midstream Partners, L.P. (MMP), Tucows Inc (TCX), and More
Hedge fund billionaire Ray Dalio knows plenty about success: He founded Bridgewater Associates, the world’s largest hedge fund with roughly $160 billion in assets.
Hedge Fund and Insider Trading News: Tom Steyer, David Shaw, Ray Dalio, Keshik Capital, Facebook Inc. (FB), Cullen/Frost Bankers, Inc. (CFR), and More
Apparently running for president is not a valid excuse for getting out of jury duty.
Is Clovis Oncology Inc (CLVS) A Good Stock To Buy?
Billionaire hedge fund managers such as David Abrams, Steve Cohen and Stan Druckenmiller can generate millions or even billions of dollars every year by pinning down high-potential...
Here’s What Hedge Funds Think About About Clovis Oncology Inc (CLVS)
"October lived up to its scary reputation—the S&P 500 falling in the month by the largest amount in the last 40 years, the only worse Octobers being '08 and the Crash of '87...
Argentiere Capital’s Returns, AUM and Holdings
Deepak Gulati's Argentiere Capital is a Zug, Switzerland-based hedge fund launched back in June 2013, with an additional office in Chicago.
Should You Avoid Clovis Oncology Inc (CLVS)?
The Insider Monkey team has completed processing the quarterly 13F filings for the September quarter submitted by the hedge funds and other money managers included in our extensive...
How Clovis Oncology Inc (CLVS) Stacks Up Against Its Market Cap Peers
The 700+ hedge funds and money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the second quarter, which unveil their equity positions...
Clovis Oncology Inc (CLVS) is Trending After TESARO Inc (TSRO) Results
Niraparib, which goes by the brand name Zejula, is an once-daily oral PARP inhibitor.
AstraZeneca PLC (ADR) (AZN)’s Lynparza Trial Results Positive In Competitive Threat To Clovis Oncology Inc (CLVS) And TESARO Inc (TSRO)
Lynparza, an ovarian cancer treatment developed by AstraZeneca PLC (ADR) (NYSE:AZN) has demonstrated its ability to slow down disease progression.
Here’s What Just Happened With AstraZeneca PLC (ADR) (AZN), TESARO Inc (TSRO) And Clovis Oncology Inc (CLVS)
It’s been a big week for PARP inhibitors.
Clovis Oncology Inc (CLVS)’s Ovarian Cancer Drug Faces Stiff Competition From AstraZeneca PLC (ADR) (AZN), TESARO Inc (TSRO)
Trials of rival drugs from AstraZeneca PLC (ADR) (NYSE:AZN) and TESARO Inc (NASDAQ:TSRO) will determine the adoption of the PARP inhibitor, Rubraca from Clovis Oncology Inc (NASDAQ...
Does Clovis Oncology Inc (CLVS) Represent a Good Addition to Your Portfolio?
The elite funds run by legendary investors such as Dan Loeb and David Tepper make hundreds of millions of dollars for themselves and their investors by spending enormous resources...
Westmoreland Coal Company (WLB), Corrections Corp Of America (CXW): Here’s Why Traders Are Piling Into These Stocks
Like Britain's decision to leave the EU, the unexpected occurred after Donald Trump beat Hillary Clinton to win the White House.
Palo Alto Investors’s Bets on ABIOMED, Inc. (ABMD), United Therapeutics Corporation (UTHR) and Other Stocks Lift Its Q3 Returns
Palo Alto Investors was founded by William Leland Edwards in 1989. The fund usually invests in companies with market capitalization less than $3 billion.
Here’s Why These Five Stocks Are in the Red Today: Clovis Oncology, Tyson Foods, Lloyds Banking Group, and More
Although the broader markets are only down moderately after today's rather disappointing jobs report, shares of five companies Clovis Oncology Inc (NASDAQ:CLVS), eBay Inc (NASDAQ...
Why Traders Are Talking About Chevron, Adobe, Petrobras, and More
After being range-bound for the last few weeks, crude promises to be a little bit more volatile in the near-term following today's release of the EIA inventory numbers and the...
Here’s Why These Five Stocks Are Trading Higher Today
Given the rising oil prices, it's not surprising that several oil stocks made it to our list of daily gainers.
Kyle Bass Makes Huge Bet Against McDonald’s, Sells Off Clovis
Although Kyle Bass of Hayman Advisors is famous for his macro trading such as shorting Japanese bonds or the housing market, his fund also places equity bets too.
Here’s Why Many Smart Money Investors Are Bullish on Clovis Oncology
Clovis Oncology Inc (NASDAQ:CLVS) is a biopharmaceutical company focused on developing and commercializing anti-cancer agents.
Our Take On The Clovis Oncology Inc (CLVS) Announcement
Clovis Oncology Inc (NASDAQ:CLVS) just reported that the FDA has accepted its new drug application (NDA) and the company is up close to 30% ahead of the market open in the US ...
A Closer Look at Five Stocks in Spotlight Following Financial Reports
Five stocks are in the spotlight following the release of their latest financial results, including DaVita HealthCare Partners Inc (NYSE:DVA), Colony Financial Inc (NYSE:CLNY...
Here’s Why These Five Stocks Are On the Move on Wednesday
Among the stocks showing more volatility than usual are TESARO Inc (NASDAQ:TSRO), Clovis Oncology Inc (NASDAQ:CLVS), PrivateBancorp Inc (NASDAQ:PVTB), Southwestern Energy Company...
Redmile Group Sticking With Healthcare Picks After Rough Q1
Redmile Group is a San Francisco-based, healthcare-focused hedge fund founded and managed by Jeremy Green, an Oxford alum with more than 20 years of experience in wealth management...
Here’s Why These 5 Stocks Are Grabbing Headlines Today
Although the CBOE Volatility Index is at 14 and crude prices are near their 2016 highs, volatility is of course alive and well among individual stocks.
Fitbit Inc (FIT) Among 5 Stocks That Are Trending Today
At a time when all three indexes are in the green, shares of Canadian Pacific Railway Limited (USA) (NYSE:CP), Norfolk Southern Corp.
What is Causing These 5 Stocks to Move Sharply on Friday?
While the indexes have had a moderately volatile day so far, shares of Clovis Oncology Inc (NASDAQ:CLVS), China Hgs Real Estate Inc (NASDAQ:HGSH), Amira Nature Foods Ltd (NYSE...
HealthCor Management LP Increases Stake In Clovis Oncology, Inc. (CLVS)
Arthur B Cohen and Joseph Healey's HealthCor Management has filed a 13G with the Securities and Exchange Commission, disclosing its position in Clovis Oncology Inc (NASDAQ:CLVS...
Palo Alto’s Top Picks for This Year Following Impressive 2015 Returns
William Leland Edwards' Palo Alto Investors has about $2.22 billion worth of regulatory assets under its management.
Redmile Group’s Top Q4 Moves as Its Long Positions Show Gains of 20% in 2015
Redmile Group is a San Francisco-based investment firm managed by Jeremy Green, which primarily focuses on the healthcare sector.
The Smart Money is Hoarding Shares of These 10 Healthcare Stocks, Part 2
In the first part in our series, we covered five healthcare stocks that the hedge funds in our database have favored heavily for one reason or another, owning a high concentration...
Top Stock Picks of Multi-Billion Dollar, Healthcare-Focused Fund Palo Alto Investors
Palo Alto Investors, founded by Wall Street veteran William Leland Edwards in 1989, is one of the biggest healthcare investment shops in the United States, with over $2 billion...
Clovis Oncology Inc (CLVS): Are Hedge Funds Right About This Stock?
We can judge whether Clovis Oncology Inc (NASDAQ:CLVS) is a good investment right now by following the lead of some of the best investors in the world and piggybacking their ideas...
Hedge Fund Sentiment Has This to Say About These Moves on 3 Healthcare Stocks
It is easy to imagine that hedge funds would not reveal their equity positions if it were not for reporting requirements enforced by the Securities and Exchange Commission.
These Four Stocks Are Getting Creamed Today
While Wall Street rallied into green territory from the opening bell on Monday, Dillard's Inc. (NYSE:DDS), Marriott International Inc.
Should You Follow Hedge Fund Sentiment Of Wednesday’s Top 3 Healthcare Gainers?
As we have covered the top losers among healthcare stocks earlier today, which included three biotech companies, it's time to take a look at some companies that have been gaining...
Microsoft Corporation (MSFT), Valeant Pharmaceuticals Intl Inc (VRX): Partner Fund Management’s Winning Bets in Healthcare and Tech
Headquartered in San Francisco, Partner Fund Management was established in 2004 by Christopher Medlock James.
Palo Alto Rejoicing at ABIOMED, Inc. (ABMD)’s 18% Spike
ABIOMED, Inc. (NASDAQ:ABMD) spiked as high as 21% in Tuesday's intraday trading to eventually close at 18% in the green at $72.48.
Sientra Inc (SIEN), TESARO Inc (TSRO) and Clovis Oncology Inc (CLVS): Orbimed’s Top New Picks
Samuel Islay's Orbimed Advisors has revealed its equity portfolio as of end of 2014, in a recent filing with the Securities and Exchange Commission.
Insider Watch: 5 Stocks Scott D. Sandell Likes
Scott Sandell, a large shareholder and director with over 30 affiliations is the insider to watch for retail investors.
Hedge Funds Are Dumping Dendreon Corporation (DNDN)
To the average investor, there are tons of methods shareholders can use to monitor the equity markets.
InterMune Inc (ITMN): Hedge Funds Aren’t Crazy About It, Insider Sentiment Unchanged
To many market players, hedge funds are perceived as delayed, old financial tools of a period lost to current times.
Is Achillion Pharmaceuticals, Inc. (ACHN) Going to Burn These Hedge Funds?
To the average investor, there are dozens of indicators market participants can use to analyze their holdings.
